TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20137761

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg b.i.d for 7 days along with standard doses of aspirin and clopidogrel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18608093

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg) - Creatine (10 g) twice daily for six months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg) - Creatine (10 g) twice daily for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 60
Study: 16102404

Group type: EXPERIMENTAL
Intervention: 1-phase treatment (bionator, headgear/biteplane, or observation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2-phase treatment (full orthodontic treatment with fixed appliances after 1 year)
Number of subjects: 200
Study: 12421836

Group type: EXPERIMENTAL
Intervention: Iron supplements from 4 to 9 mo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Iron supplements [1 mg/(kg. d)] from 6 to 9 mo
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo from 4 to 9 mo
Number of subjects: 232
Study: 10872368

Group type: EXPERIMENTAL
Intervention: Radical anterior resection with bone grafting plus six months of daily isoniazid plus rifampicin (Rad6)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Ambulant chemotherapy for six months with daily isoniazid plus rifampicin (Amb6)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Ambulant chemotherapy for nine months with daily isoniazid plus rifampicin (Amb9)
Number of subjects: 235
Study: 8557972

Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine antihypertensive therapy
Number of subjects: 91
Study: 1759583

Group type: EXPERIMENTAL
Intervention: Topical glucocorticoids
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Local allergen challenge
Number of subjects: 11
Study: 31221882

Group type: EXPERIMENTAL
Intervention: Potent topical corticosteroid (TCS) once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low potency topical corticosteroid (TCS) once daily
Number of subjects: 0
Study: 28858136

Group type: EXPERIMENTAL
Intervention: SUZY curved forceps
Number of subjects: 10

Group type: COMPARATOR
Intervention: Magill straight forceps
Number of subjects: 10
Study: 26188917

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with mitomycin C and 5‐fluorouracil
Number of subjects: 11743

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 11743

Group type: EXPERIMENTAL
Intervention: Primary chemoradiotherapy
Number of subjects: 11743
Study: 23478196

Group type: EXPERIMENTAL
Intervention: CABG with autologous bone marrow mononuclear cell transplantation (aBM‐MNC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 50
Study: 21724155

Group type: EXPERIMENTAL
Intervention: Medicine for the Earth (MFTE)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lifestyle Change Program (LCP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual cardiac care (control)
Number of subjects: 58
Study: 19861511

Group type: EXPERIMENTAL
Intervention: Calcium (2 g/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D plus Calcium
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 16710103

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 50
Study: 15622389

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indraparinux
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard agents
Number of subjects: 0
Study: 11722712

Group type: EXPERIMENTAL
Intervention: Immune milk treatment (45 g of immune milk powder twice a day for 3 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Immune milk treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (oral habit intervention only)
Number of subjects: 46
Study: 9220212

Group type: EXPERIMENTAL
Intervention: cilazapril plus conventional therapy (diuretics and digitalis)
Number of subjects: 32

Group type: COMPARATOR
Intervention: conventional therapy (diuretics and digitalis)
Number of subjects: 32
Study: 7921310

Group type: EXPERIMENTAL
Intervention: 7 days of food records for whites in New York
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: 2 days of food records for whites in Alabama
Number of subjects: 872
Study: 3314475

Group type: EXPERIMENTAL
Intervention: Amikacin-ampicillin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 112
Study: 31230020

Group type: EXPERIMENTAL
Intervention: 30 mg melatonin per day
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 28412065

Group type: EXPERIMENTAL
Intervention: Trimodal Therapy (TMT)
Number of subjects: 12843

Group type: COMPARATOR
Intervention: Radical Cystectomy (RC)
Number of subjects: 12843
Study: 25476727

Group type: EXPERIMENTAL
Intervention: Dysport (abobotulinumtoxinA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Botox (onabotulinumtoxinA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 103

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 103
Study: 23782529

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glimepiride 2 mg q.d.
Number of subjects: 24
Study: 21695875

Group type: COMPARATOR
Intervention: Liquid food intake (sweetened citronella drink) starting 6 hours after the procedure, no solid food for 24 hours.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Solid food intake resumed 6 hours after the procedure.
Number of subjects: 120
Study: 20128317

Group type: EXPERIMENTAL
Intervention: Herbal mouthrinse 1
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Herbal mouthrinse 2
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 116
Study: 16967045

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal 50 microg/spray b.i.d. and Fenoxifenadine 180 mg tablets q.d.
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.9% NaCl nasal drops b.i.d.
Number of subjects: 68
Study: 12775344

Group type: EXPERIMENTAL
Intervention: Upregulated isoprenoidal pathway with increased digoxin and dolichol levels in dyslexia, developmental delay of speech milestone, and delayed recovery from global aphasia.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altered synaptic inactivity due to changes in glycoconjugate metabolism and membrane composition.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hemispheric chemical dominance.
Number of subjects: 0
Study: 11022087

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Surgery (after exclusion of Chen and McKissock trials)
Number of subjects: 7
Study: 9605247

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Bed rest alone (Control)
Number of subjects: 148
Study: 8451894

Group type: EXPERIMENTAL
Intervention: 1.2 g Clindamycin (n = 79)
Number of subjects: 149

Group type: COMPARATOR
Intervention: 1.5 g Cefuroxim (n = 70)
Number of subjects: 149
Study: 3092849

Group type: EXPERIMENTAL
Intervention: RO 15-1788 (benzodiazepine antagonist)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30390065

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (Syntocinon®, Novartis; 10 puffs = 20 international units per treatment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29122269

Group type: EXPERIMENTAL
Intervention: Self-selected soothing music
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Headphone (no music)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 114
Study: 25066651

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) for 2 hours every week for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait list (WL) control
Number of subjects: 44
Study: 23615118

Group type: COMPARATOR
Intervention: tDCS (active)
Number of subjects: 120

Group type: COMPARATOR
Intervention: tDCS (sham)
Number of subjects: 120

Group type: COMPARATOR
Intervention: sertraline
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 22091738

Group type: EXPERIMENTAL
Intervention: CAPABLE intervention (occupational therapy, nursing, handyman visits)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention-control visits (sedentary activities)
Number of subjects: 40
Study: 19631127

Group type: EXPERIMENTAL
Intervention: Adrenaline group (0.5 mL of 1:1000 adrenaline in 500.0 mL of fortified balanced salt solution)
Number of subjects: 207

Group type: COMPARATOR
Intervention: No-adrenaline group (no adrenaline added)
Number of subjects: 207
Study: 17074540

Group type: EXPERIMENTAL
Intervention: Surgery for UI/POP
Number of subjects: 102
Study: 14987976

Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol tartrate (INB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11824739

Group type: EXPERIMENTAL
Intervention: Standardized Education (SE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Education with Telephone Counseling (SE+TC)
Number of subjects: 12
Study: 9789647

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study: 7978415

Group type: EXPERIMENTAL
Intervention: Fentanyl (1, 1.5, and 2.5 ng/mL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fentanyl (above 2.5 ng/mL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 to 2.25 ng/mL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 9
Study: 2582732

Group type: EXPERIMENTAL
Intervention: Finger systolic pressure (FSP) measurement at 10 degrees C
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for subjective assessment of symptoms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Correlation between FSP and VAS values
Number of subjects: 80
Study: 1079448

Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (MO)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bubble oxygenator (BO)
Number of subjects: 91
Study: 29273872

Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating (OD) tablets (30 mg) given orally once daily for 8 weeks (56 days) starting the day before ESD
Number of subjects: 304

Group type: COMPARATOR
Intervention: Intravenous lansoprazole (30 mg) as a continuous infusion twice daily for 3 days starting the day before ESD, followed by lansoprazole OD tablets (30 mg) orally once daily on days 4-56
Number of subjects: 304
Study: 26869062

Group type: EXPERIMENTAL
Intervention: Reduction Osteotomy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Pie-Crust Technique
Number of subjects: 106
Study: 25691686

Group type: EXPERIMENTAL
Intervention: rs6795970 single nucleotide polymorphism variant
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Common variants A1073 and P1092
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Rare missense variants V94G and R1588Q
Number of subjects: 225
Study: 23616513

Group type: EXPERIMENTAL
Intervention: Wheat rolls fortified with microencapsulated L-5-methyltetrahydrofolic acid (452 μg/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Wheat rolls fortified with equimolar folic acid (400 μg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (no added folate)
Number of subjects: 45
Study: 20693267

Group type: EXPERIMENTAL
Intervention: High intake of polyunsaturated fats (quartile 4)
Number of subjects: 9559

Group type: EXPERIMENTAL
Intervention: Dietary calcium (quartile 4)
Number of subjects: 9559

Group type: EXPERIMENTAL
Intervention: Nutrient and supplement intakes (lycopene, long-chain n-3 fatty acids, vitamin D, vitamin E, selenium)
Number of subjects: 9559

Group type: EXPERIMENTAL
Intervention: High intake of n-6 fatty acids
Number of subjects: 9559
Study: 18221509

Group type: EXPERIMENTAL
Intervention: Teenage BCG vaccination
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Infant BCG vaccination
Number of subjects: 148

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 148
Study: 17090740

Group type: EXPERIMENTAL
Intervention: Prasterone (100-200 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12714124

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 10741631

Group type: EXPERIMENTAL
Intervention: Disulfiram pretreatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Rifampin pretreatment
Number of subjects: 2
Study: 9374251

Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml, one drop once daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml, one drop twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml, three drops once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 18
Study: 1551961

Group type: EXPERIMENTAL
Intervention: Home urinary LH detection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine clinical methods
Number of subjects: 56
Study: 3893619

Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Phenol Injection
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 269
Study: 30985566

Group type: EXPERIMENTAL
Intervention: Straight leg raise test (SLR)
Number of subjects: 14
Study: 29699968

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (guided self-help)
Number of subjects: 120
Study: 26048065

Group type: EXPERIMENTAL
Intervention: non‐emotional contingency training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: non‐emotional no‐contingency training
Number of subjects: 62

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 62
Study: 24096053

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d (in patients with HAM-D17>22)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo (in patients with HAM-D17>22)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d and Placebo
Number of subjects: 427
Study: 23808647

Group type: EXPERIMENTAL
Intervention: Comprehensive continuum of care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 20530437

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone at 400 mg daily for 10 days/month for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone
Number of subjects: 40
Study: 19108019

Group type: EXPERIMENTAL
Intervention: PSTI + MP
Number of subjects: 33

Group type: COMPARATOR
Intervention: IVTA
Number of subjects: 33
Study: 16175516

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once-daily subcutaneous injections for 5-9 days
Number of subjects: 2048
Study: 14696946

Group type: EXPERIMENTAL
Intervention: Post-menopausal women
Number of subjects: 45

Group type: COMPARATOR
Intervention: Women with conservative/reactionary preference for traditional sex roles
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Menopausal Status, Educational level and social support
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Age, self-image and attitude to sex domain of the marital satisfaction scale
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Marital satisfaction
Number of subjects: 45
Study: 10918989

Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lutein (15 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study: 8646707

Group type: EXPERIMENTAL
Intervention: Paclitaxel treatment
Number of subjects: 77
Study: 1352979

Group type: EXPERIMENTAL
Intervention: Combination of hypotensive drugs including beta-blockers
Number of subjects: 304

Group type: COMPARATOR
Intervention: Combination of hypotensive drugs including diuretics instead of beta-blockers
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Patients with LVMM greater than 200 g
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Regression of LVH to less than 200 g
Number of subjects: 304
Study: 3533137

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 24
Study: 30259582

Group type: EXPERIMENTAL
Intervention: 2-mm height abutments immediately connected (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1-mm height abutments immediately connected (Group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2-mm abutments inserted in a second-stage surgery (Group C)
Number of subjects: 33
Study: 27566263

Group type: EXPERIMENTAL
Intervention: Alectinib 150 mg capsule
Number of subjects: 35

Group type: COMPARATOR
Intervention: Alectinib 20/40 mg capsules
Number of subjects: 35
Study: 25349868

Group type: EXPERIMENTAL
Intervention: 10-min Swedish back massage for 6 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 90
Study: 22429395

Group type: EXPERIMENTAL
Intervention: Epoetin (3.3 × 10(4) IU); n = 45
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (saline 0.9% solution); n = 47
Number of subjects: 92
Study: 20492838

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: COMPARATOR
Intervention: Aripiprazole and Placebo
Number of subjects: 125
Study: 18391054

Group type: EXPERIMENTAL
Intervention: Acceptance-based protocol (ACT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive control-based protocol (CONT)
Number of subjects: 20
Study: 16158740

Group type: EXPERIMENTAL
Intervention: mitoxantron+cysplatin+prednisolone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: vinorelbin + cycloplatam
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: mitoxantron + prednisolone
Number of subjects: 59
Study: 12741431

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspirin 1300 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspirin 325 mg/day
Number of subjects: 48
Study: 10442912

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% added to existing glaucoma medication regimen
Number of subjects: 96
Study: 8523297

Group type: EXPERIMENTAL
Intervention: Sutureless cataract surgery
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sutured cataract surgery
Number of subjects: 28
Study: 2212374

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (mean 27.5 mg) administered three times daily for at least 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo identical in appearance to isosorbide dinitrate
Number of subjects: 8
Study: 331868

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg and 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31838009

Group type: EXPERIMENTAL
Intervention: Oncokompas (eHealth application)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group (access to Oncokompas after 6 months)
Number of subjects: 625
Study: 31629443

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 3634

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 3634
Study: 28152989

Group type: EXPERIMENTAL
Intervention: SQ-LNS with 0, 5 or 10 mg zinc, 6 mg iron, and 400 μg vitamin A, along with malaria and diarrhea treatment.
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: SQ-LNS with 10 mg zinc.
Number of subjects: 2435

Group type: COMPARATOR
Intervention: NIC (non-intervention cohort).
Number of subjects: 2435
Study: 26094394

Group type: EXPERIMENTAL
Intervention: Dietary supplement rekicen‐RD® in combination with antibacterial therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard antibacterial therapy
Number of subjects: 64
Study: 23971711

Group type: EXPERIMENTAL
Intervention: HP‐PRRSV/PCV2 (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PCV2/HP‐PRRSV (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HP‐PRRSV+PCV2 (group 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HP‐PRRSV (group 4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PCV2 (group 5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (group 6)
Number of subjects: 30
Study: 21212375

Group type: EXPERIMENTAL
Intervention: Passive mobilization of shoulder region joints
Number of subjects: 98

Group type: COMPARATOR
Intervention: Advice and exercises designed to restore neuromuscular control at the shoulder
Number of subjects: 98
Study: 17884078

Group type: EXPERIMENTAL
Intervention: Effective applications of RF energy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ineffective applications of RF energy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Patterns of JR (sinus-junction-sinus, sinus-junction-junction, sinus-junction-block)
Number of subjects: 95
Study: 16430795

Group type: EXPERIMENTAL
Intervention: CobraPLA (PLA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 90